New scan could spot hidden tumors in rare diseases

NCT ID NCT07379463

Recruiting now Diagnosis Sponsor: Tianjin Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a special PET/CT scan using an amino acid tracer can better detect tumors in people with amino acid transport disorders, primary hyperparathyroidism, or glioma. About 500 adults will receive a single injection of the tracer and then get scanned. The goal is to see how well the scan identifies tumors and their spread, which could help doctors make more accurate diagnoses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 11C/18F-MET/FET (a radioactive tracer injected for PET/CT imaging)
What this could lead to: If successful, this could provide a more accurate way to diagnose and monitor tumors related to amino acid transport disorders, improving treatment planning.
What could go wrong: This is an early imaging study, not a treatment trial. The new scan may not prove more accurate than existing methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMINO-ACID TRANSPORT DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma inborn disorder of amino acid transport primary hyperparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMINO-ACID TRANSPORT DISORDER GLIOMA PRIMARY HYPERPARATHYROIDISM

Contacts and locations

Locations

The First Affiliated Hospital of University of Science and Technology of China
RECRUITING

Hefei, Anhui, 230000, China
Tianjin Medical University General Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.